No Data
No Data
Buy Rating for Moleculin Biotech on Promising Annamycin Trials and Undervalued Shares
Moleculin Biotech Advances to Phase 3 in AML Treatment Trial
Moleculin Biotech Unveils Corporate Strategy Update Presentation
Moleculin Announces Plans For MIRACLE Adaptive Phase 3 Clinical Trial Designed For Possible Accelerated Approval Of Annamycin In Combination With Cytarabine For The Treatment Of Relapsed Or Refractory AML
Express News | Moleculin Announces Plans for Miracle Phase 3 Pivotal Trial
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial
No Data